**Highlights of This Issue** 1085

**REVIEW**

1087  
**Targeting Wnts at the Source—New Mechanisms, New Biomarkers, New Drugs**  
Babita Madan and David M. Virshup

**SMALL MOLECULE THERAPEUTICS**

1095  
**P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity**  

1107  
**Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy**  
Barbara Lelj-Garolla, Masafumi Kumano, Eliana Beraldi, Lucia Nappi, Palma Rocchi, Diana N. Ionescu, Ladan Fazli, Amina Zoubeidi, and Martin E. Gleave

1117  
**p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer**  
John J. Tentler, Anastasia A. Ionkina, Aik Choon Tan, Timothy P. Newton, Todd M. Pitts, Magdalena J. Glogowska, Peter Kabos, Carol A. Sartorius, Kelly D. Sullivan, Joaquin M. Espinosa, S. Gail Eckhardt, and Jennifer R. Diamond

**LARGE MOLECULE THERAPEUTICS**

1130  
**High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody–Drug Conjugates**  

1141  
**Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody**  

**CANCER BIOLOGY AND SIGNAL TRANSDUCTION**

1152  
**βIII-Tubulin Regulates Breast Cancer Metastases to the Brain**  
Deepak Kanojia, Ramin A. Morshed, Lingjiao Zhang, Jason M. Miska, Jian Qiao, Julius W. Kim, Peter Pytel, Irina V. Balyasnikova, Maciej S. Lesniak, and Atique U. Ahmed

1162  
**HOTAIR Long Noncoding RNA Promotes Gastric Cancer Metastasis through Suppression of Poly(rC)-Binding Protein (PCBP) 1**  
Zi-Zhen Zhang, Zhi-Yong Shen, Yan-Ying Shen, En-Hao Zhao, Ming Wang, Chao-Jie Wang, Hui Cao, and Jia Xu

1171  
**Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition**  
Monal Mehta, Atif Khan, Shabbar Danish, Bruce G. Haflly, and Hatem E. Sabaawy

1181  
**The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses**  
Lisa Christiansson, Stina Söderlund, Sara Mangsbo, Henrik Hjorth-Hansen, Martin Högland, Berit Markevärn, Johan Richter, Leif Stenke, Satu Mustjoki, Angelica Loskog, and Ulla Olsson-Strömberg

1192  
**Endostatin Has ATPase Activity, Which Mediates Its Antiangiogenic and Antitumor Activities**  
Shan Wang, Xin-an Lu, Peng Liu, Yan Fu, Lin Jia, Shunli Zhan, and Yongzhang Luo

1202  
**Frequent Loss of NISCH Promotes Tumor Proliferation and Invasion in Ovarian Cancer via Inhibiting the FAK Signal Pathway**  
Jing Li, Xiaoying He, Ruofan Dong, Yuan Wang, Jinjin Yu, and Hailong Qiu
Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells


Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

Hung Huynh, Huai-Xiang Hao, Stephen L. Chan, David Chen, Richard Ong, Khee Chee Soo, Panisa Pochanard, David Yang, David Ruddy, Manway Liu, Adnan Derti, Marissa N. Balak, Michael R. Palmer, Yan Wang, Benjamin H. Lee, Dalila Sellami, Andrew X. Zhu, Robert Schlegel, and Alan Huang

MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide

Oihane Erice, Michael P. Smith, Rachel White, Ilhai Goicoechea, Jorge Barriuso, Chris Jones, Geoffrey P. Margison, Juan C. Acosta, Claudia Wellbrock, and Imanol Arozarena

Enhancement of the Proapoptotic Properties of Newcastle Disease Virus Promotes Tumor Remission in Syngeneic Murine Cancer Models

Sara Cuadrado-Castano, Juan Ayllon, Mena Mansour, Janis de la Iglesia-Vicente, Stefan Jordan, Shashank Tripathi, Adolfo Garcia-Sastre, and Enrique Villar

RNA Interference Using c-Myc–Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models


Enhancement of the Proapoptotic Properties of Newcastle Disease Virus Promotes Tumor Remission in Syngeneic Murine Cancer Models

Sara Cuadrado-Castano, Juan Ayllon, Mena Mansour, Janis de la Iglesia-Vicente, Stefan Jordan, Shashank Tripathi, Adolfo Garcia-Sastre, and Enrique Villar

RNA Interference Using c-Myc–Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models


The newly generated Newcastle disease virus rNDV-B1/Fas encodes the human TNF receptor Fas. Human and murine cancer cells infected by rNDV-B1/Fas displayed a modified cell death response compared with the wild-type rNDV-B1, characterized by an earlier and enhanced apoptosis response due to the overexpression of Fas following the coactivation of both extrinsic and intrinsic apoptosis pathways. The enhanced cytotoxicity shown in vitro correlated with an improved oncolytic activity and therapeutic effect of rNDV-B1/Fas virus in intratumoral-treated melanoma-bearing mice. The cover image shows murine B16-F10 melanoma cells infected by rNDV-B1/Fas virus. The human Fas receptor (red) is expressed on the surface of infected cells (green) but also internalized following induction of apoptosis. DNA was counterstained with Hoechst. For details, see the article by Cuadrado-Castano and colleagues on page 1247.

Downloaded from mct.aacrjournals.org on September 21, 2021. © 2015 American Association for Cancer Research.
Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/14/5

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/14/5. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site. |